RXRX · Recursion Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.47M | - | $5.17M | $19.22M | $14.74M | - | $26.08M | $14.42M | $13.79M | - |
| Cost of Revenue | $12.49M | - | $14.69M | $20.16M | $21.83M | - | $12.08M | $9.20M | $11.17M | - |
| Gross Profit | ($6.02M) | - | ($9.51M) | ($938.0K) | ($7.08M) | - | $14.00M | $5.22M | $2.63M | - |
| R&D | $87.90M | - | $121.06M | $128.64M | $129.63M | - | $74.60M | $73.93M | $67.56M | - |
| SG&A | $34.59M | - | $41.63M | $46.65M | $54.65M | - | $37.76M | $31.83M | $31.41M | - |
| Total Operating Expenses | $134.98M | - | $177.38M | $195.45M | $206.11M | - | $124.44M | $114.96M | $110.13M | - |
| D&A | $19.67M | - | - | - | $19.33M | - | $4.00M | $4.10M | $7.38M | - |
| Operating Income | ($128.50M) | - | ($172.20M) | ($176.23M) | ($191.37M) | - | ($98.35M) | ($100.54M) | ($96.34M) | - |
| Interest Expense | $350.0K | - | $833.0K | $480.0K | $20.0K | - | $553.0K | $394.0K | $20.0K | - |
| Income Tax | ($4.60M) | - | $3.0K | $0 | ($158.0K) | - | $167.0K | ($523.0K) | ($779.0K) | - |
| Net Income | ($117.50M) | - | ($162.25M) | ($171.90M) | ($202.49M) | - | ($95.84M) | ($97.54M) | ($91.37M) | - |
| EPS - Basic | ($0.22) | - | ($0.36) | ($0.41) | ($0.50) | - | ($0.34) | ($0.40) | ($0.39) | - |
| EPS - Diluted | ($0.22) | - | ($0.36) | ($0.41) | ($0.50) | - | ($0.34) | ($0.40) | ($0.39) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $654.47M | $743.29M | $659.84M | $525.11M | $500.45M | $594.35M | $427.65M | $474.34M | $296.33M | $391.56M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $20.35M | $18.12M | $13.94M | $19.31M | $25.09M | $21.61M | $2.26M | $3.76M | $5.12M | $3.95M |
| Current Assets | $709.56M | $812.85M | $714.11M | $587.16M | $584.14M | $714.27M | $474.17M | $522.38M | $343.62M | $438.14M |
| Total Assets | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B | $1.45B | $726.50M | $775.86M | $557.85M | $653.70M |
| Current Liabilities | $129.70M | $147.71M | $155.10M | $164.03M | $141.98M | $187.47M | $108.89M | $86.08M | $73.92M | $93.17M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $314.75M | $343.26M | $352.58M | $383.21M | $371.29M | $413.82M | $201.94M | $191.41M | $156.70M | $190.26M |
| Stockholders' Equity | $1.02B | $1.13B | $1.05B | $919.15M | $933.95M | $1.03B | $524.56M | $584.45M | $401.15M | $463.44M |
| Retained Earnings | ($2.19B) | ($2.08B) | ($1.97B) | ($1.81B) | ($1.63B) | ($1.43B) | ($1.25B) | ($1.16B) | ($1.06B) | ($967.62M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($81.10M) | - | - | - | ($131.96M) | - | - | - | ($102.30M) | - |
| Investing Cash Flow | ($338.0K) | - | - | - | ($7.27M) | - | - | - | ($6.65M) | - |
| Financing Cash Flow | ($3.47M) | - | - | - | $40.53M | - | - | - | $13.90M | - |
| CapEx | $258.0K | - | - | - | $1.83M | - | - | - | $6.65M | - |
| Free Cash Flow | ($81.36M) | - | - | - | ($133.79M) | - | - | - | ($108.95M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -93.0% | - | -183.8% | -4.9% | -48.0% | - | 53.7% | 36.2% | 19.1% | - |
| Operating margin | -1985.6% | - | -3327.6% | -916.8% | -1297.9% | - | -377.1% | -697.4% | -698.4% | - |
| EBITDA margin | -1681.6% | - | - | - | -1166.7% | - | -361.8% | -669.0% | -644.9% | - |
| Net margin | -1815.6% | - | -3135.3% | -894.2% | -1373.3% | - | -367.5% | -676.6% | -662.4% | - |
| Free cash flow margin | -1257.1% | - | - | - | -907.4% | - | - | - | -789.9% | - |
| FCF / Net income | 0.69 | - | - | - | 0.66 | - | - | - | 1.19 | - |
| R&D / Revenue | 1358.1% | - | 2339.4% | 669.2% | 879.2% | - | 286.0% | 512.8% | 489.8% | - |
| SG&A / Revenue | 534.5% | - | 804.4% | 242.7% | 370.6% | - | 144.8% | 220.8% | 227.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.8% | - | -11.6% | -13.2% | -15.5% | - | -13.2% | -12.6% | -16.4% | - |
| Return on equity | -11.5% | - | -15.5% | -18.7% | -21.7% | - | -18.3% | -16.7% | -22.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.47 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 |
| Quick ratio | 5.47 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 |
| Cash ratio | 5.05 | 5.03 | 4.25 | 3.20 | 3.52 | 3.17 | 3.93 | 5.51 | 4.01 | 4.20 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -367.2x | - | -206.7x | -367.1x | -9568.4x | - | -177.9x | -255.2x | -4817.0x | - |
| Equity multiplier | 1.31 | 1.30 | 1.34 | 1.42 | 1.40 | 1.40 | 1.38 | 1.33 | 1.39 | 1.41 |
| Liabilities / Assets | 0.23 | 0.23 | 0.25 | 0.29 | 0.28 | 0.29 | 0.28 | 0.25 | 0.28 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.01 | - | 0.04 | 0.02 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 595d | - | 346d | 350d | 419d | - | 68d | 149d | 167d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.6x | - | 2.1x | 2.3x | 2.3x | - | 3.6x | 3.1x | 5.9x | - |
| P / S | 251.1x | - | 421.5x | 109.9x | 144.5x | - | 71.4x | 126.0x | 170.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -56.1% | - | -80.2% | 33.3% | 6.9% | - | 147.6% | 30.9% | 13.7% | - |
| Revenue CAGR (3y) | -18.9% | - | -26.7% | 35.8% | 40.4% | - | 194.1% | 78.2% | 512.6% | - |
| Revenue CAGR (5y) | 155.0% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 15.0% | - | - | - | - | - | - | 219.1% | - | - |
| Operating income growth (YoY) | 32.8% | - | -75.1% | -75.3% | -98.6% | - | 1.2% | -23.0% | -37.9% | - |
| Net income growth (YoY) | 42.0% | - | -69.3% | -76.2% | -121.6% | - | -3.0% | -27.1% | -39.9% | - |
| EPS growth (YoY) | 56.0% | - | -5.9% | -2.5% | -28.2% | - | 20.9% | -5.3% | -14.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 39.2% | - | - | - | -22.8% | - | - | - | -38.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 9.7% | 9.3% | 99.6% | 57.3% | 132.8% | 123.3% | 19.8% | 24.6% | -6.7% | -4.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$74.68M totalReportable Segment$74.68M · 100.0%
Product / service
$74.68M totalLicense And Service$74.26M · 99.4%
Grant$425.0K · 0.6%
Geographic
$74.68M totalUS$39.34M · 52.7%
GB$35.34M · 47.3%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing RECURSION PHARMACEUTICALS against the 5 most active filers in the same SIC group.